Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24-week open-label study of an aliskiren-based treatment algorithm in mild to moderate hypertension
2008-002797-36Phase 4Completed
- Sponsor
- Novartis
- Start
- Jul 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aliskiren in essential hypertension, sponsored by Novartis. Primary endpoint: Proportion of patients reaching target blood pressure. Started Jul 2008; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2008-002797-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002797-36.